Active	Status	Sponsor type	Region	Phase	Filter
10 Active 0 Inactive 10 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Pham, Mirko
ESCAPE-NEXT, NCT04462536 / 2020-002360-30: Efficacy and Safety of Nerinetide in Participants With Acute Ischemic Stroke Undergoing Endovascular Thrombectomy Excluding Thrombolysis	Completed	3	850	Europe, Canada, US, RoW	Placebo, Nerinetide, NA-1	NoNO Inc., University of Calgary	Stroke, Acute	08/23	08/23
Ehmer, Ursula
IMMUWIN, NCT04522544: Durvalumab and Tremelimumab in Combination With Either Y-90 SIRT or DEB-TACE for Intermediate Stage HCC	Recruiting	2	55	Europe	Tremelimumab, Durvalumab, Y-90 SIRT, DEB-TACE	Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, AstraZeneca, Hannover Medical School	Hepatocellular Carcinoma Non-resectable, HCC	03/25	09/25
NCT04511455: Cabozantinib for Patients with Hepatocellular Carcinoma (HCC) Refractory to First Line Treatment	Completed	2	22	Europe	Cabozantinib	Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Ipsen	Hepatocellular Carcinoma Non-resectable, Metastatic Hepatocellular Carcinoma	12/24	12/24
Kandulski, Arne
No trials found
Reiter, Florian
No trials found